跳至主要内容
临床试验/ACTRN12612000763842
ACTRN12612000763842尚未招募未知

A study to investigate the potential use of circulating tumour DNA as a marker of residual disease that predicts later recurrence in patients diagnosed with stage I and II pancreatic adenocarcinoma

udwig Institute for Cancer Research0 个研究点目标入组 100 人开始时间: 2012年7月18日最近更新:
适应症

试验速览

阶段
未知
状态
尚未招募
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

年龄范围
18 Years 至 o limit(—)
性别
All

入选标准

  • 1. Patients with resectable pancreatic adenocarcinoma who are to have a resection of their tumour.
  • 2. ECOG performance status 0 - 2.
  • 3. Patients willing to provide written informed consent.

排除标准

  • 1. History of another primary cancer within the last 5 years, with the exception of non-melanomatous skin cancer and carcinoma in situ of the cervix.
  • 2. Medical or psychiatric condition or occupational responsibilities that may preclude compliance with the protocol.
  • 3. Patients that are not accessible for follow-up.
  • 4. Preoperative chemotherapy or radiotherapy.

研究者

发起方
udwig Institute for Cancer Research

相似试验